A Phase 3 interventional study of Upadacitinib and Placebo for Upadacitinib in Crohn's Disease, sponsored by AbbVie. Completed at 432 sites in 49 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-23.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Crohn Disease by AbbVie — 6 open to participants now, 14 under way, 6 of them phase 3. Crohn Disease · AbbVie.
Among the 55 studies in Crohn Disease by AbbVie, this one is the 9th largest by enrollment of the 27 interventional ones that give a count, is one of 6 that started in 2017, is one of 16 in phase 3, and was the 32nd registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →6 of the 55 studies in Crohn Disease by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Canada, Israel and 2 more countries
Ages 18–75
AbbVie · Sites in Italy
Ages 18+
AbbVie · Sites in Belgium
Ages 18+
AbbVie · Sites in United States, Austria, Belgium and 30 more countries
Ages 18–75
AbbVie · Sites in United States, Belgium, Bulgaria and 18 more countries
Ages 2–17
By country, each count listing its studies:
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 6 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 526 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 220 across the 27 interventional studies, 252 across the 26 observational. Of the 38 that completed or were terminated, 28 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
2 of the studies in Crohn Disease by AbbVie that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06063967Phase 3AbbVieA Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. | 2027-03 |
| NCT03345823Phase 3AbbVieA Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 55 studies in Crohn Disease by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in adults with moderately and severely active Crohn's disease (CD).
This study includes two parts:
In Part 1, participants will be randomized in a 2:1 ratio to upadacitinib 45 mg once daily (QD) or matching placebo for 12 weeks. The randomization will be stratified by baseline corticosteroid use (yes or no), endoscopic disease severity (Simplified Endoscopic Score for Crohn's disease [SES-CD] \< 15 and ≥ 15), and number of prior biologics with prior inadequate response or intolerance (0, 1, > 1).
Participants who do not achieve clinical response at Week 12 will be able to enroll in Part 2 to receive a double-blind extended treatment with upadacitinib until Week 24. Clinical response is defined as a ≥ 30% decrease in average daily very soft or liquid stool frequency (SF) and/or ≥ 30% decrease in average daily abdominal pain (AP) score (both not worse than Baseline).
Participants who achieve clinical response at Week 12 may be eligible to enter the 52-week, double-blind, maintenance portion of Study M14-430 (NCT03345823).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Demonstrated an inadequate response or intolerance to one or more conventional and/or biologic therapies (oral locally acting , intravenous or oral corticosteroids, or biologic therapies for CD), in the opinion of the investigator.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive placebo once daily for 12 weeks in Part 1. Clinical non-responders will receive 45 mg upadacitinib once daily for 12 weeks in Part 2.
Drug: Upadacitinib · Drug: Placebo for Upadacitinib
Participants will receive 45 mg upadacitinib once daily for 12 weeks in Part 1. Clinical non-responders will receive 30 mg upadacitinib once daily for 12 weeks in Part 2.
Drug: Upadacitinib
Oral; Tablet
Also known as: ABT-494, RINVOQ
Oral; Tablet
Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12
The co-primary endpoint for United States (US)/Food and Drug Administration (FDA) regulatory purposes was clinical remission based on CDAI at Week 12. CDAI is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as presence of complications (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma gangrenosum/aphthous stomatitis, anal fissure/fistula/abscess, other fistula, and fever), the use of antidiarrheal medicines, presence of an abdominal mass, hematocrit, and body weight. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease. Clinical remission is defined as a CDAI score less than 150.
Time frame: Week 12
Percentage of Participants With Clinical Remission Per Patient-Reported Outcomes (PROs) at Week 12
The co-primary endpoint for European Union (EU)/European Medicines Agency (EMA) regulatory purposes was clinical remission defined based on two patient reported outcomes, average daily stool frequency (SF) and average daily abdominal pain score (APS). Clinical remission per PROs was defined as average daily very soft or liquid SF ≤ 2.8 and average daily APS ≤ 1.0 and neither worse than Baseline. Participants recorded APS and the number of very soft or liquid SF daily in an electronic diary. Abdominal pain was rated on a scale from 0 (none) to 3 (severe). The average daily very soft or liquid SF and APS were calculated using the 4-7 most recent useable days of patient-report outcomes (i.e., excluding days with missing entries or associated with endoscopy procedures) out of the last 14 days prior to the Week 12 visit.
Time frame: Week 12
Percentage of Participants With Endoscopic Response at Week 12
Endoscopic response at Week 12 was a co-primary endpoint for both the US/FDA and EU/EMA regulatory purposes. Endoscopic response was defined as greater than 50% decrease in Simple Endoscopic Score for Crohn's Disease (SES-CD) from Baseline of the induction study (or for participants with an SES-CD of 4 at Baseline, at least a 2-point reduction from Baseline), as scored by independent external and blinded central readers. The SES-CD evaluates 4 endoscopic variables (ulcer size, ulcerated surface, affected surface, and narrowing, each on a scale from 0 (none) to 3 in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and ranges from 0 to 56, where higher scores indicate more severe disease.
Time frame: Baseline and Week 12
Percentage of Participants With Endoscopic Remission at Week 12
Endoscopic remission is defined as an SES-CD ≤ 4 and at least 2 point reduction from Baseline and no subscore \> 1 in any individual variable,as scored by independent external and blinded central readers. The SES-CD evaluates 4 endoscopic variables (ulcer size, ulcerated surface, affected surface, and narrowing, each on a scale from 0 (none) to 3 in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and ranges from 0 to 56, where higher scores indicate more severe disease.
Time frame: Baseline and Week 12
Percentage of Participants Who Discontinued Corticosteroid Use for Crohn's Disease and Achieved Clinical Remission Per CDAI at Week 12
Corticosteroid-free clinical remission is defined as participants who discontinued corticosteroid use for CD and achieved clinical remission per CDAI at Week 12, assessed for participants taking corticosteroids for CD at Baseline. CDAI is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as presence of complications (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma gangrenosum/aphthous stomatitis, anal fissure/fistula/abscess, other fistula, and fever), the use of antidiarrheal medicines, presence of an abdominal mass, hematocrit, and body weight. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease. Clinical remission is defined as CDAI score less than 150.
Time frame: Week 12
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at Week 12
The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days, including physical fatigue (e.g., I feel tired), functional fatigue (e.g., trouble finishing things), emotional fatigue (e.g., frustration), and social consequences of fatigue (e.g., limits social activity). Participants respond to the questions on a scale from 0 (not at all) to 4 (very much). The FACIT-Fatigue score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue score ranges from 0 to 52, where higher scores represent less fatigue. A positive change from Baseline indicates improvement.
Time frame: Baseline and Week 12
Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 12
The Inflammatory Bowel Disease Questionnaire (IBDQ) is used to assess health-related quality of life (HRQoL) in patients with inflammatory bowel disease. It consists of 32 questions evaluating bowel and systemic symptoms, as well as emotional and social functions. Each question is answered on a scale from 1 (worst) to 7 (best). The total score ranges from 32 to 224 with higher scores indicating better health-related quality of life. A positive change from Baseline indicates improvement.
Time frame: Baseline and Week 12
Percentage of Participants Achieving Clinical Response 100 (CR-100) at Week 2
Clinical response 100 (CR-100) is defined as a decrease of at least 100 points in CDAI from Baseline. CDAI is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as presence of complications (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma gangrenosum/aphthous stomatitis, anal fissure/fistula/abscess, other fistula, and fever), the use of antidiarrheal medicines, presence of an abdominal mass, hematocrit, and body weight. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease.
Time frame: Baseline and Week 2
Percentage of Participants Achieving Clinical Response 100 (CR-100) at Week 12
Clinical response 100 (CR-100) is defined as a decrease of at least 100 points in CDAI from Baseline. CDAI is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as presence of complications (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma gangrenosum/aphthous stomatitis, anal fissure/fistula/abscess, other fistula, and fever), the use of antidiarrheal medicines, presence of an abdominal mass, hematocrit, and body weight. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease.
Time frame: Baseline and Week 12
Percentage of Participants With Clinical Remission Per CDAI at Week 4
CDAI is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as presence of complications (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma gangrenosum/aphthous stomatitis, anal fissure/fistula/abscess, other fistula, and fever), the use of antidiarrheal medicines, presence of an abdominal mass, hematocrit, and body weight. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease. Clinical remission is defined as CDAI score less than 150.
Time frame: Week 4
Percentage of Participants With Hospitalizations Due to Crohn's Disease (CD) During the 12-Week Induction Period
This was assessed by reviewing participant's hospitalization data.
Time frame: 12 weeks
Percentage of Participants With Resolution of Extra-Intestinal Manifestation (EIMs) at Week 12
EIMs are defined as manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver. Only participants with any EIM present at Baseline were included in the analysis of resolution of EIMs. Resolution of EIMs was defined as absence of all EIMs at the Week 12 visit.
Time frame: Week 12
Percentage of Participants With Clinical Remission Per PROs at Week 4
Clinical remission per PROs was defined as average daily very soft or liquid SF ≤ 2.8 and average daily APS ≤ 1.0 and neither worse than Baseline. Participants recorded APS and the number of liquid or very soft SF daily in an electronic diary. Abdominal pain was rated on a scale from 0 (none) to 3 (severe). The average daily very soft or liquid SF and APS were calculated using the 4-7 most recent useable days of patient-reported outcomes (i.e., excluding days with missing entries or associated with endoscopy procedures) out of the last 14 days prior to the Week 4 visit.
Time frame: Week 4
Percentage of Participants Who Discontinued Corticosteroid Use for Crohn's Disease and Achieved Clinical Remission Per PROs at Week 12
Corticosteroid-free clinical remission is defined as participants who discontinued corticosteroid use for CD and achieved clinical remission per PROs at Week 12, assessed for participants taking corticosteroids for CD at Baseline. Clinical remission per PROs was defined as average daily very soft or liquid stool frequency (SF) ≤ 2.8 and average daily APS ≤ 1.0 and neither worse than Baseline. Participants recorded APS and the number of liquid or very soft SF daily in an electronic diary. Abdominal pain was rated on a scale from 0 (none) to 3 (severe). The average daily liquid or very soft SF and APS were calculated using the 4-7 most recent useable days of patient-reported outcomes (i.e., excluding days with missing entries or associated with endoscopy procedures) out of the last 14 days prior to the Week 12 visit.
Time frame: Week 12
Eligible participants with moderately to severely active Crohn's disease (CD) were randomized at 209 sites in 42 countries. The study consisted of a 12-week double-blind induction treatment period, and a 12-week extended treatment period for participants who did not achieve clinical response at the end of the induction treatment period.
| Milestone | Part 1: Placebo | Part 1: Upadacitinib 45 mg | Part 2: Placebo / Upadacitinib 45 mg | Part 2: Upadacitinib 45 mg / Upadacitinib 30 mg |
|---|---|---|---|---|
| Started | 176 | 350 | 0 | 0 |
| Received study drug | 176 | 350 | 0 | 0 |
| Completed | 154 | 330 | 0 | 0 |
| Not completed | 22 | 20 | 0 | 0 |
| Withdrew: Adverse event | 8 | 12 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 3 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 8 | 3 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 0 | 0 |
| Milestone | Part 1: Placebo | Part 1: Upadacitinib 45 mg | Part 2: Placebo / Upadacitinib 45 mg | Part 2: Upadacitinib 45 mg / Upadacitinib 30 mg |
|---|---|---|---|---|
| Started | 0 | 0 | 57 | 59 |
| Completed | 0 | 0 | 49 | 49 |
| Not completed | 0 | 0 | 8 | 10 |
| Withdrew: Adverse event | 0 | 0 | 2 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 3 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 5 |
| Withdrew: Coronavirus disease-2019 (covid-19) infection | 0 | 0 | 0 | 1 |
| Withdrew: Covid-19 logistical restrictions | 0 | 0 | 1 | 0 |
| Withdrew: Other | 0 | 0 | 1 | 1 |
The co-primary endpoint for United States (US)/Food and Drug Administration (FDA) regulatory purposes was clinical remission based on CDAI at Week 12. CDAI is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as presence of complications (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma gangrenosum/aphthous stomatitis, anal fissure/fistula/abscess, other fistula, and fever), the use of antidiarrheal medicines, presence of an abdominal mass, hematocrit, and body weight. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease. Clinical remission is defined as a CDAI score less than 150.
| percentage of participants | Placebo | Upadacitinib 45 mg QD |
|---|---|---|
| Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 | 29.1 (22.4 to 35.8) | 49.5 (44.2 to 54.8) |
The co-primary endpoint for European Union (EU)/European Medicines Agency (EMA) regulatory purposes was clinical remission defined based on two patient reported outcomes, average daily stool frequency (SF) and average daily abdominal pain score (APS). Clinical remission per PROs was defined as average daily very soft or liquid SF ≤ 2.8 and average daily APS ≤ 1.0 and neither worse than Baseline. Participants recorded APS and the number of very soft or liquid SF daily in an electronic diary. Abdominal pain was rated on a scale from 0 (none) to 3 (severe). The average daily very soft or liquid SF and APS were calculated using the 4-7 most recent useable days of patient-report outcomes (i.e., excluding days with missing entries or associated with endoscopy procedures) out of the last 14 days prior to the Week 12 visit.
| percentage of participants | Placebo | Upadacitinib 45 mg QD |
|---|---|---|
| Percentage of Participants With Clinical Remission Per Patient-Reported Outcomes (PROs) at Week 12 | 22.2 (16.0 to 28.3) | 50.7 (45.5 to 56.0) |
Endoscopic response at Week 12 was a co-primary endpoint for both the US/FDA and EU/EMA regulatory purposes. Endoscopic response was defined as greater than 50% decrease in Simple Endoscopic Score for Crohn's Disease (SES-CD) from Baseline of the induction study (or for participants with an SES-CD of 4 at Baseline, at least a 2-point reduction from Baseline), as scored by independent external and blinded central readers. The SES-CD evaluates 4 endoscopic variables (ulcer size, ulcerated surface, affected surface, and narrowing, each on a scale from 0 (none) to 3 in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and ranges from 0 to 56, where higher scores indicate more severe disease.
| percentage of participants | Placebo | Upadacitinib 45 mg QD |
|---|---|---|
| Percentage of Participants With Endoscopic Response at Week 12 | 13.1 (8.1 to 18.0) | 45.5 (40.3 to 50.8) |
Endoscopic remission is defined as an SES-CD ≤ 4 and at least 2 point reduction from Baseline and no subscore \> 1 in any individual variable,as scored by independent external and blinded central readers. The SES-CD evaluates 4 endoscopic variables (ulcer size, ulcerated surface, affected surface, and narrowing, each on a scale from 0 (none) to 3 in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and ranges from 0 to 56, where higher scores indicate more severe disease.
| percentage of participants | Placebo | Upadacitinib 45 mg QD |
|---|---|---|
| Percentage of Participants With Endoscopic Remission at Week 12 | 7.4 (3.5 to 11.3) | 28.9 (24.2 to 33.7) |
Corticosteroid-free clinical remission is defined as participants who discontinued corticosteroid use for CD and achieved clinical remission per CDAI at Week 12, assessed for participants taking corticosteroids for CD at Baseline. CDAI is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as presence of complications (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma gangrenosum/aphthous stomatitis, anal fissure/fistula/abscess, other fistula, and fever), the use of antidiarrheal medicines, presence of an abdominal mass, hematocrit, and body weight. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease. Clinical remission is defined as CDAI score less than 150.
| percentage of participants | Placebo | Upadacitinib 45 mg QD |
|---|---|---|
| Percentage of Participants Who Discontinued Corticosteroid Use for Crohn's Disease and Achieved Clinical Remission Per CDAI at Week 12 | 15.7 (6.8 to 24.7) | 42.9 (34.2 to 51.5) |
The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days, including physical fatigue (e.g., I feel tired), functional fatigue (e.g., trouble finishing things), emotional fatigue (e.g., frustration), and social consequences of fatigue (e.g., limits social activity). Participants respond to the questions on a scale from 0 (not at all) to 4 (very much). The FACIT-Fatigue score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue score ranges from 0 to 52, where higher scores represent less fatigue. A positive change from Baseline indicates improvement.
| score on a scale | Placebo | Upadacitinib 45 mg QD |
|---|---|---|
| Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at Week 12 | 5.0 (3.2 to 6.8) | 11.3 (10.0 to 12.5) |
The Inflammatory Bowel Disease Questionnaire (IBDQ) is used to assess health-related quality of life (HRQoL) in patients with inflammatory bowel disease. It consists of 32 questions evaluating bowel and systemic symptoms, as well as emotional and social functions. Each question is answered on a scale from 1 (worst) to 7 (best). The total score ranges from 32 to 224 with higher scores indicating better health-related quality of life. A positive change from Baseline indicates improvement.
| score on a scale | Placebo | Upadacitinib 45 mg QD |
|---|---|---|
| Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 12 | 24.423 (19.007 to 29.840) | 46.265 (42.495 to 50.035) |
Clinical response 100 (CR-100) is defined as a decrease of at least 100 points in CDAI from Baseline. CDAI is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as presence of complications (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma gangrenosum/aphthous stomatitis, anal fissure/fistula/abscess, other fistula, and fever), the use of antidiarrheal medicines, presence of an abdominal mass, hematocrit, and body weight. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease.
| percentage of participants | Placebo | Upadacitinib 45 mg QD |
|---|---|---|
| Percentage of Participants Achieving Clinical Response 100 (CR-100) at Week 2 | 20.4 (14.4 to 26.5) | 32.2 (27.3 to 37.1) |
Clinical response 100 (CR-100) is defined as a decrease of at least 100 points in CDAI from Baseline. CDAI is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as presence of complications (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma gangrenosum/aphthous stomatitis, anal fissure/fistula/abscess, other fistula, and fever), the use of antidiarrheal medicines, presence of an abdominal mass, hematocrit, and body weight. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease.
| percentage of participants | Placebo | Upadacitinib 45 mg QD |
|---|---|---|
| Percentage of Participants Achieving Clinical Response 100 (CR-100) at Week 12 | 37.3 (30.1 to 44.5) | 56.6 (51.4 to 61.8) |
CDAI is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as presence of complications (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma gangrenosum/aphthous stomatitis, anal fissure/fistula/abscess, other fistula, and fever), the use of antidiarrheal medicines, presence of an abdominal mass, hematocrit, and body weight. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease. Clinical remission is defined as CDAI score less than 150.
| percentage of participants | Placebo | Upadacitinib 45 mg QD |
|---|---|---|
| Percentage of Participants With Clinical Remission Per CDAI at Week 4 | 26.7 (20.2 to 33.3) | 37.1 (32.1 to 42.2) |
This was assessed by reviewing participant's hospitalization data.
| percentage of participants | Placebo | Upadacitinib 45 mg QD |
|---|---|---|
| Percentage of Participants With Hospitalizations Due to Crohn's Disease (CD) During the 12-Week Induction Period | 5.1 (1.9 to 8.4) | 3.7 (1.7 to 5.7) |
EIMs are defined as manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver. Only participants with any EIM present at Baseline were included in the analysis of resolution of EIMs. Resolution of EIMs was defined as absence of all EIMs at the Week 12 visit.
| percentage of participants | Placebo | Upadacitinib 45 mg QD |
|---|---|---|
| Percentage of Participants With Resolution of Extra-Intestinal Manifestation (EIMs) at Week 12 | 20.9 (11.8 to 30.1) | 28.5 (21.3 to 35.7) |
Clinical remission per PROs was defined as average daily very soft or liquid SF ≤ 2.8 and average daily APS ≤ 1.0 and neither worse than Baseline. Participants recorded APS and the number of liquid or very soft SF daily in an electronic diary. Abdominal pain was rated on a scale from 0 (none) to 3 (severe). The average daily very soft or liquid SF and APS were calculated using the 4-7 most recent useable days of patient-reported outcomes (i.e., excluding days with missing entries or associated with endoscopy procedures) out of the last 14 days prior to the Week 4 visit.
| percentage of participants | Placebo | Upadacitinib 45 mg QD |
|---|---|---|
| Percentage of Participants With Clinical Remission Per PROs at Week 4 | 14.8 (9.5 to 20.0) | 35.7 (30.7 to 40.7) |
Corticosteroid-free clinical remission is defined as participants who discontinued corticosteroid use for CD and achieved clinical remission per PROs at Week 12, assessed for participants taking corticosteroids for CD at Baseline. Clinical remission per PROs was defined as average daily very soft or liquid stool frequency (SF) ≤ 2.8 and average daily APS ≤ 1.0 and neither worse than Baseline. Participants recorded APS and the number of liquid or very soft SF daily in an electronic diary. Abdominal pain was rated on a scale from 0 (none) to 3 (severe). The average daily liquid or very soft SF and APS were calculated using the 4-7 most recent useable days of patient-reported outcomes (i.e., excluding days with missing entries or associated with endoscopy procedures) out of the last 14 days prior to the Week 12 visit.
| percentage of participants | Placebo | Upadacitinib 45 mg QD |
|---|---|---|
| Percentage of Participants Who Discontinued Corticosteroid Use for Crohn's Disease and Achieved Clinical Remission Per PROs at Week 12 | 12.5 (4.4 to 20.6) | 44.4 (35.8 to 53.1) |
Collected over Part 1: 12 weeks Part 2: 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Placebo | 0/176 (0%) | 12/176 (6.8%) | 37/176 (21%) |
| Part 1: Upadacitinib 45 mg | 0/350 (0%) | 24/350 (6.9%) | 92/350 (26.3%) |
| Part 2: Placebo / Upadacitinib 45 mg | 0/57 (0%) | 4/57 (7%) | 14/57 (24.6%) |
| Part 2: Upadacitinib 45 mg / Upadacitinib 30 mg | 1/59 (1.7%) | 6/59 (10.2%) | 13/59 (22%) |
| Event | Part 1: Placebo | Part 1: Upadacitinib 45 mg | Part 2: Placebo / Upadacitinib 45 mg | Part 2: Upadacitinib 45 mg / Upadacitinib 30 mg |
|---|---|---|---|---|
| CROHN'S DISEASEGastrointestinal disorders | 5/176 | 7/350 | 1/57 | 2/59 |
| INTESTINAL PERFORATIONGastrointestinal disorders | 0/176 | 0/350 | 1/57 | 0/59 |
| COVID-19 PNEUMONIAInfections and infestations | 1/176 | 0/350 | 1/57 | 0/59 |
| FALLInjury, poisoning and procedural complications | 0/176 | 0/350 | 1/57 | 0/59 |
| FEMORAL NECK FRACTUREInjury, poisoning and procedural complications | 0/176 | 0/350 | 1/57 | 0/59 |
| ACUTE RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders | 0/176 | 0/350 | 1/57 | 0/59 |
| ENTERITISGastrointestinal disorders | 0/176 | 0/350 | 0/57 | 1/59 |
| INTESTINAL OBSTRUCTIONGastrointestinal disorders | 0/176 | 2/350 | 0/57 | 1/59 |
| COVID-19Infections and infestations | 0/176 | 0/350 | 0/57 | 1/59 |
| GASTROENTERITIS VIRALInfections and infestations | 0/176 | 0/350 | 0/57 | 1/59 |
| Event | Part 1: Placebo | Part 1: Upadacitinib 45 mg | Part 2: Placebo / Upadacitinib 45 mg | Part 2: Upadacitinib 45 mg / Upadacitinib 30 mg |
|---|---|---|---|---|
| CROHN'S DISEASEGastrointestinal disorders | 13/176 | 5/350 | 1/57 | 3/59 |
| ACNESkin and subcutaneous tissue disorders | 1/176 | 24/350 | 3/57 | 1/59 |
| NASOPHARYNGITISInfections and infestations | 6/176 | 16/350 | 2/57 | 4/59 |
| ANAEMIABlood and lymphatic system disorders | 8/176 | 21/350 | 3/57 | 2/59 |
| COVID-19Infections and infestations | 0/176 | 3/350 | 3/57 | 1/59 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 8/176 | 9/350 | 3/57 | 1/59 |
| RASHSkin and subcutaneous tissue disorders | 4/176 | 13/350 | 3/57 | 1/59 |
| PYREXIAGeneral disorders | 2/176 | 14/350 | 1/57 | 3/59 |
Intention-to-treat (ITT) population for the 12-week double-blind induction period includes all randomized participants who received at least one dose of double-blind study drug during Part 1.
| Age, Continuous(years) | Placebo | Upadacitinib 45 mg | Total |
|---|---|---|---|
| Mean | 39.3 ± 13.63 | 39.7 ± 13.71 | 39.6 ± 13.67 |
| Age, Customized(Participants) | Placebo | Upadacitinib 45 mg | Total |
|---|---|---|---|
| 18 years - < 40 years | 91 | 193 | 284 |
| 40 years - < 65 years | 80 | 142 | 222 |
| ≥ 65 years | 5 | 15 | 20 |
| Sex: Female, Male(Participants) | Placebo | Upadacitinib 45 mg | Total |
|---|---|---|---|
| Female | 82 | 161 | 243 |
| Male | 94 | 189 | 283 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Upadacitinib 45 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 27 | 35 |
| Not Hispanic or Latino | 168 | 323 | 491 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Upadacitinib 45 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 36 | 73 | 109 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 17 | 21 |
| White | 130 | 258 | 388 |
| More than one race | 6 | 2 | 8 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Baseline Corticosteroid Use(Participants) | Placebo | Upadacitinib 45 mg | Total |
|---|---|---|---|
| Yes | 64 | 126 | 190 |
| No | 112 | 224 | 336 |
| Number of Previously Failed Biologics(Participants) | Placebo | Upadacitinib 45 mg | Total |
|---|---|---|---|
| Zero | 98 | 189 | 287 |
| One | 28 | 58 | 86 |
| More than one | 50 | 103 | 153 |
| Endoscopic Disease Severity(Participants) | Placebo | Upadacitinib 45 mg | Total |
|---|---|---|---|
| SES-CD < 15 | 110 | 218 | 328 |
| SES-CD ≥ 15 | 66 | 132 | 198 |
4 further baseline measures are reported on the registry.
Showing the first 100 of 432 sites across 49 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Dec 2017 to primary completion in Oct 2021, 46 months.
Results were first posted in Nov 2022, 1 year 1 month after primary completion.
Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 46 months is close to that.
Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Upadacitinib